597 related articles for article (PubMed ID: 2492189)
1. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
2. Treatment of familial hypercholesterolemia with drugs in children.
Stein EA
Arteriosclerosis; 1989; 9(1 Suppl):I145-51. PubMed ID: 2912428
[TBL] [Abstract][Full Text] [Related]
3. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
4. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
5. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
Pappu AS; Illingworth DR
J Lab Clin Med; 1989 Nov; 114(5):554-62. PubMed ID: 2809398
[TBL] [Abstract][Full Text] [Related]
6. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Erkelens DW
Cardiology; 1990; 77 Suppl 4():33-8. PubMed ID: 2073670
[TBL] [Abstract][Full Text] [Related]
7. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
8. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Geisel J; Oette K; Burrichter H
Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
[TBL] [Abstract][Full Text] [Related]
9. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
[TBL] [Abstract][Full Text] [Related]
10. Pravastatin: a new drug for the treatment of hypercholesterolemia.
Jungnickel PW; Cantral KA; Maloley PA
Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. [Hypercholesterolemia: therapeutic approach].
Alessandri C; Peverini F
Clin Ter; 1991 Jun; 137(6):373-97. PubMed ID: 1832610
[TBL] [Abstract][Full Text] [Related]
13. Treating hyperlipidemia, Part III: Drug therapy.
Smith DA; Karmally W; Brown WV
Geriatrics; 1987 Aug; 42(8):55-9, 62. PubMed ID: 3110017
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment of dyslipoproteinemia.
Hunninghake DB
Endocrinol Metab Clin North Am; 1990 Jun; 19(2):345-60. PubMed ID: 2192877
[TBL] [Abstract][Full Text] [Related]
16. Lovastatin: a new cholesterol-lowering agent.
McKenney JM
Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
[TBL] [Abstract][Full Text] [Related]
17. Currently available hypolipidaemic drugs and future therapeutic developments.
Farmer JA; Gotto AM
Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
[TBL] [Abstract][Full Text] [Related]
18. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
20. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Brocard JJ; Keller U; Oberhänsli A; Riesen WF
Schweiz Med Wochenschr; 1991 Jun; 121(26):977-83. PubMed ID: 1862314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
